Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia

Kidney International, Supplement

Volumn 57, Issue 75, 2000, Pages

  Fine, Leon G ^a,b   Bandyopadhay, Debasish ^a   Norman, Jill T ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Fibrosis; Hypoxia; Progressive renal disease; Proteinuria; Tubulointerstitium

Indexed keywords

ALBUMIN; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; COLLAGEN TYPE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; OXYGEN; PLATELET DERIVED GROWTH FACTOR; RAMIPRIL; RENIN; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTHESIS; HYPOXIA; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; TISSUE OXYGENATION; ANOXIA; CHRONIC DISEASE; KIDNEY TUBULE; PATHOLOGY; REVIEW; SCAR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANOXIA; CHRONIC DISEASE; CICATRIX; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; KIDNEY TUBULES; PROTEINURIA;

EID: 0034037110     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.07512.x     Document Type: Conference Paper

References (27)

1. FINE LG: Preventing the progression of human renal disease. Have rational therapeutic principles emerged? Kidney Int 33:116-128, 1988
2. JACOBSON H: Chronic renal failure: Pathophysiology. Lancet 338:419-427, 1991
3. BOHLE A, WEHRMANN M, BOGENSCHÜTZ O, BATZ C, VOGL W, SCHMITT H, MÜLLER CA, MÜLLER GA: The long term prognosis of primary glomerulonephritides. A morphological and clinical analysis of 1747 cases. Pathol Res Pract 188:908-924, 1992
4. ANDERSON S, BRENNER BM: Progressive renal disease: a disorder of adaptation. Q J Med 70:185-189, 1989
5. REMUZZI G, RUGGENTI P, BENIGNI A: Understanding the nature of renal disease progression. Kidney Int 51:12-15, 1997
6. BURTON CJ, WALLS J: Interstitial inflammation and scarring: Messages from the proximal tubular cells. Nephrol Dial Transpl 11:1505-1523, 1996
7. ZOJA C, BENIGNI A, REMUZZI G: Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp Nephrol 7:420-428, 1999
8. THE GISEN GROUP (GRUPPO ITALIANO DI STUDI EPIDEMEDILOGICI IN NEPHROLOGIA): Randomised placebo-controlled trail of the effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
9. DE VENUTO G, ANDREOTTI C, MATTAREI M, PEGORETTI G: Long-term Captopril therapy at low doses reduces albumin excretion in patients with essential hypertension and no sign of renal impairment. J Hypertens 3 (Suppl. 2):S143-S145, 1985
10. RUILOPE LM, ALCAZAR JM, HERNANDEZ E, PRAGA M, LAHERA V, RODICIO JL: Long-term influences of anithypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 45 (Suppl. 45):S171-S173, 1994
11. BIGAZZI R, BIANCHI S, BALDARI D, SGHERRI G, BALDARI G, CAMPESE VM: Long-term effects of a converting enzyme inhibitor and a calcium channel blocker on urinary albumin excretion in patients with essential hypertension. Am J Hypertens 6:108-113, 1992
12. FINE LG, ORPHANIDES C, NORMAN JT: Progressive renal disease: The chronic hypoxia hypothesis. Kidney Int 53 (Suppl. 65):S74-S78, 1998
13. BAUER C, KURTZ A (EDITORS): Forefronts in Nephrology: Oxygen sensing on the cellular and molecular levels. Kidney Int 51:371-608, 1997
14. BUNN HF, POYNTON R: Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76:839-885, 1996
15. SHIH S-C, CLAFFEY KP: Hypoxia regulation of gene expression in mammalian cells. Int J Exp Pathol 70:347-357, 1998
16. RATCLIFFE PJ, O'ROURKE JF, MAXWELL PH, PUGH CW: Oxygen sensing, hypoxia-inducible factor 1 and the regulation of gene expression. J Exp Biol 201:1153-1162, 1998
17. ORPHANIDES C, FINE LG, NORMAN JT: Hyoxia stimulates proximal tubular cell matrix production via a TGF-β1 independent mechanism. Kidney Int 52:637-647, 1997
18. Deleted in proof.
19. BIRKEDAL-HANSEN H, MOORE WGI, BODDEN MK, WINDSOR LJ, BIRKEDAL-HANSEN B, DECARLO A, ENGLER JA: Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4:197-250, 1993
20. STETLER-STEVENSON WG: Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 148:1345-1350, 1996
21. DENHARDT DT, FENG B, EDWARDS DR, COCUZZI ET, MALYANKAR UM: Tissue inhibitor of metalloproteinases (TIMP aka ERP): Structure, control of expression and biological functions. Pharmacol Ther 59:329-341, 1993
22. GOMEZ DE, ALONSO DF, YOSHIJI H, THORGIERSSON UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74:111-122, 1997
23. EDDY A: Molecular insights into renal fibrosis. J Am Soc Nephrol 7:2495-2508, 1996
24. BORDER W, NOBLE N: TGF-β in kidney fibrosis: a target for gene therapy. Kidney Int 51:1388-1396, 1997
25. ENHOLM B, PAAVONEN K, RISITMAKI A, KUMAR V, GUNJI Y, KLEFSTROM J, KIVINEN L, LAIHO M, OLOFSSON B, JOUKOV V, ERIKSSON U, ALITALO K: Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14:2475-2483, 1997
26. GRÖNE H-J, SIMON M, GRÖNE EF: Expression of vascular endothelial growth factor in renal vascular disease and renal transplants. J Pathol 177:259-267, 1995
27. BOHLE A, GISE HV, MACKENSEN-HAEN S, STARK-JAKOB B: The obliteration of the post-glomerular capillaries and its influence upon the function of both glomeruli and tubuli. Klin Wochenschr 59:1043-1051, 1981